85681-95-4

Basic information

• Product Name: 5-amino-2-propylphenol
• Synonyms: 5-amino-2-propylphenol;Einecs 288-233-6
• CAS NO: 85681-95-4
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.20562
• EINECS: 288-233-6
• Mol File: 85681-95-4.mol

Chemical Properties

• Melting Point: 109-110 °C
• Boiling Point: 288°C at 760 mmHg
• Flash Point: 128°C
• Appearance: /
• Density: 1.084g/cm³
• Vapor Pressure: 0.00138mmHg at 25°C
• Refractive Index: 1.582
• PKA: 10.54±0.10(Predicted)
• CAS DataBase Reference: 5-amino-2-propylphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-2-propylphenol(85681-95-4)
• EPA Substance Registry System: 5-amino-2-propylphenol(85681-95-4)

Safety Data

• Hazardous Substances Data: 85681-95-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H13NO/c1-2-3-7-4-5-8(10)6-9(7)11/h4-6,11H,2-3,10H2,1H3

Upstream product

• 18979-60-7 4-propylresorcinol 
• 857621-80-8 2-acetoxy-4-acetylamino-1-propyl-benzene 
• 1821-39-2 2-propylaniline 
• 72635-75-7 5-nitro-2-propyl-aniline 
• 876314-60-2 5-nitro-2-n-propylphenol 
• 28583-72-4 N-(3-hydroxy-4-propylphenyl)acetamide 

Downstream Products

• 857621-80-8 2-acetoxy-4-acetylamino-1-propyl-benzene 
• 28583-72-4 N-(3-hydroxy-4-propylphenyl)acetamide 

Relevant articles and documents

SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER

The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group;; R2 , R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase

Following computational analyses, potential non-nucleoside inhibitors of HIV-1 reverse transcriptase have been pursued through synthesis and assaying for anti-viral activity. The general class Het-NH-Ph-U has been considered, where Het is an aromatic heterocycle and U is an unsaturated, hydrophobic group. Results for compounds with Het = 2-thiazoyl and 2-pyrimidinyl are the focus of this report.